MAPT and Alzheimer disease: To support this hypothesis, a population-based study by Nho et al. [51], including 1581 participants with a mean age of 70 years, showed that patients with AD and NAFLD with elevated serum transaminases had poorer cognitive performances for memory and executive composite scores, increased Aβ-plaques deposition, and higher levels of phosphorylated tau/total tau protein in the cerebrospinal fluid (CSF) [51].